Video

What to Consider Before Choosing a Melanoma Treatment Plan

Author(s):

Claire Friedman, MD

Claire Friedman, Memorial Sloan Kettering Cancer Center, discusses some of the factors that doctors and elderly patients with melanoma should discuss before deciding on a treatment plan with immunotherapy. Immunotherapy is not one-size-fits all, and patients should be informed of the pros and cons of each option.

Claire Friedman, Memorial Sloan Kettering Cancer Center, discusses some of the factors that doctors and elderly patients with melanoma should discuss before deciding on a treatment plan with immunotherapy. Immunotherapy is not one-size-fits all, and patients should be informed of the pros and cons of each option.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Illustration of tumor.
March 28th 2025

Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

Spencer Feldman
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.
Top Cancer Headlines from 2023
January 2nd 2024

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer
March 6th 2025

Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer

Ryan Scott
Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.
Image of Dr. Fakih.
February 27th 2025

ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer

Dr. Marwan Fakih
The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.